Regulation

Another year of firsts in FDA’s new drug approvals

Targeted therapies beat out immuno-oncology, new modalities in 2020’s crop of new drug approvals

The pandemic didn’t slow drug approvals in the U.S., but the market is still waiting for new modalities and the next wave of immuno-oncology therapies.

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and new drug constructs.

FDA’s Center for Drug Evaluation